Navigation Links
First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Date:12/12/2007

Progress of Phase I Programme With Oral Iclaprim "Rolling" NDA for Intravenous Iclaprim in cSSSI; Electronic Submission of

First Modules due Before Year-end 2007

REINACH, Switzerland, December 12 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) announced today the enrolment and dosing of the first patients in the Phase II clinical study with intravenous iclaprim in the treatment of hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia (VAP) / healthcare-associated pneumonia (HCAP).

In addition, Arpida announced results of a Phase I study with oral iclaprim. The primary aim of the study was to assess the safety and tolerability of single ascending doses of an oral capsule formulation of iclaprim in healthy volunteers.

Moreover, Arpida today announced that the first modules of the New Drug Application (NDA) for intravenous iclaprim in its first indication, cSSSI, are ready and will be filed before year-end 2007. The filing of the NDA package is expected to be completed by the end of February 2008.

First patients enrolled in Phase II trial with intravenous iclaprim in HAP/VAP/HCAP

Patient recruitment has started and several additional clinical centres are expected to start recruiting within the next few weeks. The trial remains on track for completion in 2008.

HAP/VAP/HCAP as a potential second indication could substantially enhance iclaprim's prospects as a potent novel therapy against multi-drug resistant bacteria. In the area of pneumonia, the need for new drugs addressing MRSA-infections is particularly pressing.

The Phase II trial is designed as a multi-centre, randomised, double-blind, comparative study. The efficacy and safety of two different dosing regimens of iclaprim will be compared to the current standard of care vancomycin. More than 130 patients will be enrolled. Patients will be treated for 7-14 days and a Test-of-Cure (TOC) visit will be performed 7-14
'/>"/>

SOURCE Arpida Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Deep Knowledge Ventures ... Forum on ‘Commercialising Longevity Research’ and welcomed a ... the London Bioscience Innovation Center for the event, ... Aging Analytics Ltd. The meeting highlighted the need ... research for age-related disease, as well as the ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Terascala, the ... announced that Alan Swahn, a former vice president of ... team as vice president of marketing. Terascala’s software when ... and NetApp create the highest performance and most reliable ... appointed to guide Terascala’s channel expansion and broaden its ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., the ... relaunch of his highly informative blog, now named Stem Cells ... are Stem Cells ?” Dr. Harman’s purpose for blogging ... basics of stem cell therapy so that pet owners can ... when considering regenerative medicine. , A veterinarian by trade, Dr. ...
(Date:7/10/2014)... 10, 2014 EvoDerma ’s NOOME Anti-Aging ... rejuvenating device now comes with a second treatment cup to ... , The new cup is thinner on the edges for ... target rough, thin and uneven surfaces on the face, neck ... a stimulating treatment on areas such as the cheeks and ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... a surge in demand for nanotech tools in the ... by a New York consulting firm that focuses on ... also projected that sales of nanotech tools could double ... nanotechnology focuses on remarkable applications ranging from computer displays ...
... Hiring talent is a serious business. Many companies maintain ... matching the right person with the right skills to ... dollars are routinely spent on all manner of testing ... thinking styles, psychologies and talents of potential hires. Countless ...
... ago, while attending a conference on equity capital, the ... more than a few snickers from the participants. ... along with the entrepreneur's personal funds is nothing to ... Entrepreneurship Monitor (GEM) report. , ,William D. Bygrave, ...
Cached Biology Technology:Corporate clients will dominate surge in nanotech tool demand, study projects 2Corporate clients will dominate surge in nanotech tool demand, study projects 3Hiring in the name of talent 2Hiring in the name of talent 3Hiring in the name of talent 4Family reunion? Don't forget your business plan 2Family reunion? Don't forget your business plan 3
(Date:7/10/2014)... 2014  Pomerantz LLP has filed a class ... the "Company")(NYSE-MKT: PVCT) and certain of its officers.  ... Court, Middle District of Tennessee ... class consisting of all persons or entities who ... 17, 2013 and May 22, 2014, both dates ...
(Date:7/10/2014)... 1, 2014 Smart technology emphasis grows ... and improved security: NXT-ID, Inc. (OTCBB: NXTD), eBay Inc. (NASDAQ: ... ), Apple Inc. (NASDAQ: AAPL ), Visa Inc. ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused ... the second series of 30 second spots on CNBC for ...
(Date:7/10/2014)... It is a great honor for Avery ... the world-renowned Thoracic and Cardiovascular surgeon, Mark E Ginsburg, ... Ginsburg, with over 34 years of experience, is currently ... Samaritan Regional Medical Center. Dr. Ginsburg has been implanting ... is considered an expert in the implantation of the ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... twice as often as men, but estrogen might not be ... of the preliminary findings in the lab of Florida State ... Medicine. He recently was awarded a five-year, $1.8 million grant ... sex differences in anxiety. His research team also is working ...
... drugs is a huge industry with an annual turnover of ... extremely serious. Half of the malaria medication sold there could ... UK have now developed a technique that could resolve the ... have a prototype ready. It will resemble a small briefcase, ...
... Lizards are an important indicator species for understanding ... a crucial index for evaluating species health, but lizards ... recurring problem of spontaneous tail loss when lizards are ... way of evaluating these lizards. Dr. Shai Meiri of ...
Cached Biology News:Why does anxiety target women more? FSU researcher awarded $1.8 million grant to find out 2Problem of fake medicines in developing countries could be solved 2Getting a tail up on conservation? 2
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Tris-Hepes kit of BG-163 & BG-165 (order number BG-166)...
Incorporating the innovative InGaAs detection system the Cary 6000i is the worlds most advanced UV-Vis-NIR spectrophotometer delivering superior signal to noise performance and outstanding sensitivit...
Biology Products: